MX2020010687A - Composiciones de oligonucleotidos y metodos de uso de las mismas. - Google Patents
Composiciones de oligonucleotidos y metodos de uso de las mismas.Info
- Publication number
- MX2020010687A MX2020010687A MX2020010687A MX2020010687A MX2020010687A MX 2020010687 A MX2020010687 A MX 2020010687A MX 2020010687 A MX2020010687 A MX 2020010687A MX 2020010687 A MX2020010687 A MX 2020010687A MX 2020010687 A MX2020010687 A MX 2020010687A
- Authority
- MX
- Mexico
- Prior art keywords
- present disclosure
- disclosure provides
- methods
- muscular dystrophy
- oligonucleotide compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/02—Phosphorylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/09—Pyrimidine radicals with arabinosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Entre otras cosas, la presente divulgación proporciona oligonucleótidos diseñados, composiciones y métodos de uso de los mismos. En algunas realizaciones, la presente divulgación proporciona tecnologías útiles para reducir los niveles de transcritos. En algunas realizaciones, la presente divulgación proporciona tecnologías útiles para modular el corte y empalme de transcritos. En algunas realizaciones, las tecnologías proporcionadas pueden alterar el corte y empalme de un transcrito de distrofina (DMD). En algunas realizaciones, la presente divulgación proporciona métodos para tratar enfermedades, tales como la distrofia muscular de Duchenne, la distrofia muscular de Becker, etc.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862656949P | 2018-04-12 | 2018-04-12 | |
US201862670709P | 2018-05-11 | 2018-05-11 | |
US201862715684P | 2018-08-07 | 2018-08-07 | |
US201862723375P | 2018-08-27 | 2018-08-27 | |
US201862776432P | 2018-12-06 | 2018-12-06 | |
PCT/US2019/027109 WO2019200185A1 (en) | 2018-04-12 | 2019-04-11 | Oligonucleotide compositions and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020010687A true MX2020010687A (es) | 2021-01-20 |
Family
ID=68163789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020010687A MX2020010687A (es) | 2018-04-12 | 2019-04-11 | Composiciones de oligonucleotidos y metodos de uso de las mismas. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220306573A1 (es) |
EP (1) | EP3775203A4 (es) |
JP (2) | JP2021521140A (es) |
KR (1) | KR20210005057A (es) |
CN (1) | CN112004928A (es) |
AU (1) | AU2019252680A1 (es) |
BR (1) | BR112020020670A2 (es) |
CA (1) | CA3096667A1 (es) |
IL (1) | IL277889A (es) |
MX (1) | MX2020010687A (es) |
SG (1) | SG11202009877XA (es) |
WO (1) | WO2019200185A1 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2015104762A (ru) | 2012-07-13 | 2018-08-31 | Уэйв Лайф Сайенсес Лтд. | Хиральный контроль |
PT2872485T (pt) | 2012-07-13 | 2021-03-05 | Wave Life Sciences Ltd | Grupo auxiliar assimétrico |
KR20230152178A (ko) | 2014-01-16 | 2023-11-02 | 웨이브 라이프 사이언시스 리미티드 | 키랄 디자인 |
RU2708237C2 (ru) | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Модифицированные олигонуклеотиды и способ их получения |
MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
MA43822A (fr) | 2016-03-13 | 2018-11-28 | Wave Life Sciences Ltd | Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides |
EP3463386A4 (en) | 2016-06-03 | 2020-03-04 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDES, COMPOSITIONS AND METHOD THEREFOR |
US10988763B2 (en) | 2016-06-22 | 2021-04-27 | Proqr Therapeutics Ii B.V. | Single-stranded RNA-editing oligonucleotides |
MA46905A (fr) | 2016-11-23 | 2019-10-02 | Wave Life Sciences Ltd | Compositions et procédés de synthèse de phosphoramidites et d'oligonucléotides |
CN110997692A (zh) | 2017-06-02 | 2020-04-10 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
CN111050806A (zh) | 2017-06-02 | 2020-04-21 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
US11718638B2 (en) | 2017-06-21 | 2023-08-08 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
WO2019032607A1 (en) | 2017-08-08 | 2019-02-14 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS |
AU2018333065B2 (en) | 2017-09-18 | 2024-04-18 | Wave Life Sciences Ltd. | Technologies for oligonucleotide preparation |
SG11202001783YA (en) | 2017-10-12 | 2020-03-30 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods thereof |
AU2019316103A1 (en) | 2018-08-02 | 2021-03-11 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
JP2022525541A (ja) * | 2019-03-20 | 2022-05-17 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド調製に有用な技術 |
CN114555621A (zh) | 2019-08-15 | 2022-05-27 | Ionis制药公司 | 键修饰的寡聚化合物及其用途 |
MX2022007491A (es) * | 2019-12-19 | 2022-08-15 | Nippon Shinyaku Co Ltd | Acido nucleico antisentido que permite la omision de exones. |
AU2021274944A1 (en) | 2020-05-22 | 2022-12-15 | Wave Life Sciences Ltd. | Double stranded oligonucleotide compositions and methods relating thereto |
CN112430645A (zh) * | 2020-12-09 | 2021-03-02 | 北京华瑞康源生物科技发展有限公司 | 一种多重实时荧光pcr法检测人dmd基因拷贝数的相对定量方法及试剂盒 |
CN114763367A (zh) * | 2021-01-14 | 2022-07-19 | 施能康生物科技有限公司 | 化合物、缀合物及其用途 |
CA3224782A1 (en) | 2021-06-23 | 2022-12-29 | Nippon Shinyaku Co., Ltd. | Combination of antisense oligomers |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
CA3226457A1 (en) * | 2021-07-30 | 2023-02-02 | Amy WALKER | Nanoparticles and peptides for the delivery of cargos to muscle cells |
EP4124345A1 (en) * | 2021-07-30 | 2023-02-01 | 4basebio UK Ltd | Nanoparticles for muscle delivery |
AU2022324471A1 (en) * | 2021-08-05 | 2024-02-15 | Sanegene Bio Usa Inc. | 1'-alkyl modified ribose derivatives and methods of use |
WO2023152371A1 (en) | 2022-02-14 | 2023-08-17 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
WO2023168014A2 (en) * | 2022-03-02 | 2023-09-07 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof for exon skipping |
CN114600803B (zh) * | 2022-03-15 | 2023-05-09 | 北京协和建昊医药技术开发有限责任公司 | 一种斑马鱼cyp3a4代谢酶抑制模型、建立方法及应用 |
WO2024013361A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
WO2024013360A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
WO2024110565A1 (en) | 2022-11-24 | 2024-05-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
WO2024121373A1 (en) | 2022-12-09 | 2024-06-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5852188A (en) * | 1990-01-11 | 1998-12-22 | Isis Pharmaceuticals, Inc. | Oligonucleotides having chiral phosphorus linkages |
ES2099718T3 (es) * | 1990-07-02 | 1997-06-01 | Hoechst Ag | Analogos de oligonucleotidos con uniones internucleotidicas de 3'-3' o 5'-5' terminales. |
US5512668A (en) * | 1991-03-06 | 1996-04-30 | Polish Academy Of Sciences | Solid phase oligonucleotide synthesis using phospholane intermediates |
US6242589B1 (en) * | 1998-07-14 | 2001-06-05 | Isis Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides having modified internucleoside linkages |
AR040996A1 (es) * | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
ES2361325T3 (es) * | 2004-06-28 | 2011-06-16 | The University Of Western Australia | Oligonucleótidos antisentido para inducir la omisión de exón y métodos de uso de los mismos. |
JP2006248949A (ja) * | 2005-03-09 | 2006-09-21 | Univ Nagoya | ヌクレオシド誘導体、ヌクレオチド誘導体及びそれらの製造方法 |
NZ584793A (en) * | 2007-10-26 | 2012-05-25 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
BRPI0923225A2 (pt) * | 2008-12-02 | 2016-10-04 | Chiralgen Ltd | metodo para sintese de acidos nucleicos modificados no atomo de fosforo |
CN104603271B (zh) * | 2012-07-03 | 2019-07-19 | 马林生物科技有限公司 | 用于治疗肌肉萎缩症患者的寡核苷酸 |
RU2015104762A (ru) * | 2012-07-13 | 2018-08-31 | Уэйв Лайф Сайенсес Лтд. | Хиральный контроль |
SG11201500243WA (en) * | 2012-07-13 | 2015-04-29 | Shin Nippon Biomedical Lab Ltd | Chiral nucleic acid adjuvant |
KR20230152178A (ko) * | 2014-01-16 | 2023-11-02 | 웨이브 라이프 사이언시스 리미티드 | 키랄 디자인 |
RU2708237C2 (ru) * | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Модифицированные олигонуклеотиды и способ их получения |
MA43072A (fr) * | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
MA46427A (fr) * | 2015-10-09 | 2018-08-15 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
EP3463386A4 (en) * | 2016-06-03 | 2020-03-04 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDES, COMPOSITIONS AND METHOD THEREFOR |
-
2019
- 2019-04-11 KR KR1020207032342A patent/KR20210005057A/ko unknown
- 2019-04-11 BR BR112020020670-9A patent/BR112020020670A2/pt unknown
- 2019-04-11 US US17/046,752 patent/US20220306573A1/en active Pending
- 2019-04-11 CN CN201980025941.1A patent/CN112004928A/zh active Pending
- 2019-04-11 EP EP19784832.8A patent/EP3775203A4/en active Pending
- 2019-04-11 AU AU2019252680A patent/AU2019252680A1/en active Pending
- 2019-04-11 SG SG11202009877XA patent/SG11202009877XA/en unknown
- 2019-04-11 CA CA3096667A patent/CA3096667A1/en active Pending
- 2019-04-11 MX MX2020010687A patent/MX2020010687A/es unknown
- 2019-04-11 JP JP2020555234A patent/JP2021521140A/ja active Pending
- 2019-04-11 WO PCT/US2019/027109 patent/WO2019200185A1/en active Application Filing
-
2020
- 2020-10-08 IL IL277889A patent/IL277889A/en unknown
-
2023
- 2023-07-05 JP JP2023110962A patent/JP2023139036A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11202009877XA (en) | 2020-11-27 |
US20220306573A1 (en) | 2022-09-29 |
JP2023139036A (ja) | 2023-10-03 |
WO2019200185A1 (en) | 2019-10-17 |
EP3775203A4 (en) | 2022-03-30 |
EP3775203A1 (en) | 2021-02-17 |
CN112004928A (zh) | 2020-11-27 |
KR20210005057A (ko) | 2021-01-13 |
AU2019252680A1 (en) | 2020-10-22 |
CA3096667A1 (en) | 2019-10-17 |
IL277889A (en) | 2020-11-30 |
BR112020020670A2 (pt) | 2021-03-02 |
JP2021521140A (ja) | 2021-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020010687A (es) | Composiciones de oligonucleotidos y metodos de uso de las mismas. | |
MX2022004101A (es) | Composiciones de oligonucleotidos y metodos de uso de las mismas. | |
MY201938A (en) | Methods and compositions for modulating splicing | |
MA45819A (fr) | Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés | |
CR20200347A (es) | Inhibidores pd-1/pd-l1 | |
WO2019092507A3 (en) | Crispr/cas systems for treatment of dmd | |
MX2023009712A (es) | Composiciones oligonucleotidicas y sus metodos. | |
WO2018115527A3 (en) | Mers coronavirus vaccine | |
MX2018005107A (es) | Composiciones y metodos para la terapia relacionada con la microbiota fecal. | |
WO2016106401A3 (en) | Rna agents for p21 gene modulation | |
MX2022007576A (es) | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. | |
MX2022013356A (es) | Avv que codifica mirna dirigido al gen htt y usos del mismo. | |
EP2426203A3 (en) | Agents useful in treating facioscapulohumeral muscular dystrophy | |
EP3757215A3 (en) | Compositions and methods for modulating growth hormone receptor expression | |
NZ627896A (en) | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy | |
WO2020123645A8 (en) | Combination therapy for treating muscular dystrophy | |
MX2009013295A (es) | Estuche y metodo para aplicaciones de tratamiento para el cabello. | |
PH12021550558A1 (en) | Modulators of pnpla3 expression | |
SG11201908747YA (en) | (meth)acrylic copolymer, method for producing same, resin composition and antifouling paint composition | |
MX2016017386A (es) | Metodo de reduccion del encrespado mediante el uso de una composicion que comprende una silicona reticulable. | |
BR112013030733A2 (pt) | combinação sinergistica para inibição de polimerização de monômeros vinila | |
MX2020002038A (es) | Métodos para el tratamiento de distrofia muscular. | |
JOP20200291A1 (ar) | معدلات التعبير عن apol1 | |
PH12021551365A1 (en) | Compositions and methods for treating and preventing amyotrophic lateral sclerosis | |
MX2020005373A (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis. |